27-10-2025 04:21 Home | Feedback | Sitemap| Careers | Contact Us |FAQ | Investor Complaints Data | Investor Charter Stock-Broker | Investor DP
  You Are On: IPO
IPO
Current Issues
Forthcoming Issues
Closed Issues
New Listings
Best Performers
IPO Performance
IPO News
IPO Analysis
Basis Of Allotment
Draft Prospectus
Best Performers
Senores Pharmaceuticals Ltd.
Issue Open Date 20-Dec-24  
Issue Closing Date 24-Dec-24  
Application Money 100  
Allotment Money  
Price Band 372 - 391  
Minimium Application No. 38  
Issue Size (Shares) 8534681  
Market Lot 1  
Objective
1.Investment in one of our Subsidiaries, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility.2.Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company.3.Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiary.4.Funding the working capital requirements of our Company.5.Investment in our Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”) and Ratnatris Pharmaceutical Private Limited (“Ratnatris”) to fund their working capital requirements.6.Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
Category No. of Shares No. of Shares Subscription Ratio
  Offered / Reserved Bid For  
Non-Institutional Investors   2319879   222963632   96.1100264281025  
Qualified Institutional Buyers   4593216   434778102   94.6565765685742  
Retail Individual Investors   4593216   434778102   94.6565765685742  
Business Description
We are a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets across various therapeutic areas and dosage forms, with a presence in Emerging Market
Promoter's Holding
Total Share Capital   22176079  
Offered to Public   8534681  
Promoter's Holding (Pre-Issue)   66.67  
Promoter's Holding (Post-Issue)   45.76  
More
Address
1101 To 1103
11th Floor
South Tower
One 42 Opp. Jayantilal Park
Ambali Bopal Road
Ahmedabad ,
Gujarat ,
380054
Phone : 079-29999857
Email : info@senorespharma.com
Website : www.senorespharma.com
Registrar
MUFG Intime India Pvt Ltd.
C 101
247 Park
LBS Marg
Vikhroli (West)
Mumbai
Listed at
BSE, NSE
Lead Manager
Ambit Pvt Ltd.
Equirus Capital Pvt Ltd
Nuvama Wealth Management Ltd.
Promoters
Ashokkumar Vijaysinh Barot
Swapnil Jatinbhai Shah
 

Attention Investors : Prevent Unauthorised transactions in your account. Update your mobile numbers/email IDs with your stock brokers / DP and Exchanges / Depository. Receive information of your transactions directly from Exchanges / Depository on your mobile/email at the end of the day .......... Issued in the interest of investors

KYC is one time exercise while dealing in securities markets – once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

“No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application from to authorize your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account.’

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.